{"id":60295,"date":"2026-05-05T12:22:29","date_gmt":"2026-05-05T12:22:29","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/60295\/"},"modified":"2026-05-05T12:22:29","modified_gmt":"2026-05-05T12:22:29","slug":"readout-newsletter-roche-rocket-tessera-alnylam-gsk","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/60295\/","title":{"rendered":"Readout Newsletter: Roche, Rocket, Tessera, Alnylam, GSK"},"content":{"rendered":"

Want to stay on top of the science and politics driving biotech today?\u00a0Sign up<\/a>\u00a0to get our biotech newsletter in your inbox.<\/p>\n

Morning! Today, we see that the FDA is extending its review period for multiple myeloma drug Blenrep. We also see more layoffs at a gene-editing company, and hear Alnylam\u2019s CEO advocate for a new policy when it comes to Medicare price negotiations.<\/p>\n

The need-to-know this morning<\/p>\n

Roche reported second-quarter earnings<\/a>.\u00a0<\/p>\n

Rocket Pharmaceuticals announced a restructuring<\/a>\u00a0that will include layoffs affecting 30% of its employees. The company is reducing its cash burn by 25% to focus on gene therapies for cardiovascular conditions. It will no longer pursue the approval of a gene therapy for Fanconi anemia.\u00a0<\/p>\n

FDA delays GSK\u2019s Blenrep decision again<\/p>\n

From my colleague Andrew Joseph: The wait for a Food and Drug Administration approval decision\u00a0on GSK\u2019s blood cancer drug Blenrep is going to take a little longer.<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Want to stay on top of the science and politics driving biotech today?\u00a0Sign up\u00a0to get our biotech newsletter…\n","protected":false},"author":2,"featured_media":60296,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[336,324,1000,338,134],"class_list":{"0":"post-60295","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-biotechnology","9":"tag-drug-development","10":"tag-drug-prices","11":"tag-research","12":"tag-roche"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116521949449266851","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/60295","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=60295"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/60295\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/60296"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=60295"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=60295"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=60295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}